8045 Lamon Avenue
52 articles with Exicure, Inc.
Exicure, Inc. announced today that Exicure and its collaborators at The Ohio State University Wexner Medical Center will show preclinical data demonstrating the performance of Exicure’s SNA compound designed for use in spinal muscular atrophy.
Exicure, Inc. announced that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the Jefferies 2018 Healthcare Conference.
For some time, the difference between a biotechnology company and a pharmaceutical company was straightforward. A biotechnology focused on developing drugs with a biological basis. Pharmaceutical companies focused on drugs with a chemical basis. But what about nanotechnology? Is that biotechnology?
Exicure Announces Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis
Exicure, Inc. announced results from the Phase 1b clinical trial of its compound, AST-005.
Exicure, Inc. reported full year financial results for the year ended December 31, 2017 and provided an update on corporate progress.
As of September 30, 2017 Exicure had cash and cash equivalents of $22.9 million compared to $19.6 million as of December 31, 2016.
Exicure announced it had closed on $11.2M in private financing.
Exicure Closes Additional $11.2 Million in Private Financing to Advance Its Gene Regulatory and Immunotherapeutic Programs
Exicure today announced the closing of approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager Info Investments LTD, Knoll Capital Management and Purple Arch Ventures.
Exicure Announces Dosing Of First Patient In Phase I Trial For The Treatment Of Chronic Plaque Psoriasis